RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today presented results from two separate studies of SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection—at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. The first presentation outlined results from an in vitro study demonstrating that, unlike other cyclophilin inhibitors, SCY-635 is not associated with an increased risk of hyperbilirubinemia in 15-day clinical studies. These data suggest that SCY-635 may be uniquely positioned in the cyclophilin inhibitor class. The second presentation outlined the effects of SCY-635 in in vitro studies on collagen production and fibrosis and suggests that SCY-635 may have an anti-fibrotic effect independent of demonstrated anti-HCV activity. SCY-635 will enter Phase 2 studies in HCV in the second half of 2010.
